Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients

American Heart Journal

Volumn 159, Issue 4, 2010, Pages

  Dauerman, Harold L ^a   Bhatt, Deepak L ^b,c   Gretler, Daniel D ^d   French, Patricia A ^e   Smyth, Susan S ^f   Becker, Richard C ^g  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Portola Pharmaceuticals Inc   (United States)

^e Left Lane Communications ^*  (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; PRASUGREL; TICAGRELOR; TIROFIBAN; WARFARIN;

ACUTE CORONARY SYNDROME; AGING; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DECISION MAKING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYSIS; GROUPS BY AGE; HEALTH CARE QUALITY; HEART INFARCTION; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; PATIENT CARE; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; STABLE ANGINA PECTORIS; THROMBOSIS; VASCULAR SURGERY;

EID: 77950249728     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.01.010     Document Type: Review

References (63)

1. Alexander K.P., Newby L.K., Cannon C.P., et al. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes. Circulation 115 (2007) 2549-2569
2. Kung H.C., Hoyert D.L., Xu J.Q., et al. Deaths: final data for 2005. Natl Vital Stat Rep 56 (2008)
3. Kung H.C., Hoyert D.L., Xu J.Q., et al. Deaths: final data for 2005 (2008), National Center for Health Statistics, Hyattsville (MD)
4. American Heart Association. Older Americans and cardiovascular diseases-statistics (2009), American Heart Association, Dallas
5. GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 141 (2001) 190-199
6. Alexander K.P., Roe M.T., Chen A.Y., et al. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 46 (2005) 1479-1487
7. Lee P.Y., Alexander K.P., Hammill B.G., et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 286 (2001) 708-713
8. GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition. Lancet 357 (2001) 1905-1914
9. Ndrepepa G., Kastrati A., Mehilli J., et al. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. Circulation 114 (2006) 2040-2046
10. Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. JAMA 295 (2006) 1531-1538
11. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356 (2000) 2037-2044
12. Giugliano R.P., White J.A., Bode C., et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360 (2009) 2176-2190
13. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338 (1998) 1488-1497
14. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
15. Trial Investigators C.U.R.E. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
16. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
17. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1183
18. Lopes R.D., Alexander K.P., Manoukian S.V., et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 53 (2009) 1021-1030
19. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
20. Harrington R.A., Stone G.W., McNulty S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361 (2009) 2318-2329
21. Bhatt D.L., Lincoff A.M., Gibson C.M., et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361 (2009) 2330-2341
22. Bhatt D.L., Lincoff A.M., Gibson C.M., et al. Results of the CHAMPION PLATFORM trial. Presented at the American Heart Association 2009 Scientific Sessions, Orlando, Florida, November 14-18 (2009) Abstract 09-LBCT-19955-AHA
23. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009) 1045-1057
24. Bhatt D.L., Roe M.T., Peterson E.D., et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 292 (2004) 2096-2104
25. Bhatt D.L. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med 357 (2007) 2078-2081
26. European public assessment report for authorised medicinal products for human use-Efient (prasugrel). Available at http://www.emea.europa.eu/humandocs/Humans/EPAR/efient/efient.htm. Last accessed May 29, 2009.
27. Effient (prasugrel) tablets: highlights of prescribing information. Indianapolis: Daiichi Sankyo Inc. and Eli Lilly and Company; July 2009.
28. Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol 60 (2006) 144-151
29. Goswami K., Bhatla B.D., and Shankar R. Platelet protein damage by free radicals and glycation in vitro: the pathological consequences. Indian J Clin Biochem 15 (2000) 11-16
30. Goubareva I., Gkaliagkousi E., Shah A., et al. Age decreases nitric oxide synthesis and responsiveness in human platelets and increases formation of monocyte-platelet aggregates. Cardiovasc Res 75 (2007) 793-802
31. Dollemore D. Blood vessels and aging: the rest of the journey. Aging hearts and arteries (2008), National Institute on Aging, Bethesda (MD)
32. Maia L.F., Mackenzie I.R., and Feldman H.H. Clinical phenotypes of cerebral amyloid angiopathy. J Neurol Sci 257 (2007) 23-30
33. National Institutes of Health. Fact sheet: progeria. August 2006. Accessed available at. www.nih.gov/about/researchresultsforthepublic/Progeria.pdf Last accessed April 9, 2009
34. Lans H., and Hoeijmakers J.H. Cell biology: ageing nucleus gets out of shape. Nature 440 (2006) 32-44
35. Hayflick L., and Moorhead P.S. The serial cultivation of human diploid cell strains. Exp Cell Res 25 (1961) 585-621
36. Capell B.C., Collins F.S., and Nabel E.G. Mechanisms of cardiovascular disease in accelerated aging syndromes. Circ Res 101 (2007) 13-26
37. Catheterization Genetics (CATHGEN) Web site. About CATHGEN. Available at http://cathgen.duhs.duke.edu/modules/cath_about/index.php?id=1. Last accessed April 9, 2009.
38. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2008) 354-362
39. Fitzmaurice D.A., Blann A.D., and Lip G.Y.H. Bleeding risks of antithrombotic therapy. BMJ 325 (2002) 828-831
40. Eikelboom J.W., Mehta S.R., Anand S.S., et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-782
41. Manoukian S.V., Feit F., Mehran R., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes. J Am Coll Cardiol 49 (2007) 1362-1368
42. Feit F., Voeltz M.D., Attubato M.J., et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol 100 (2007) 1364-1369
43. Kinnaird T.D., Stabile E., Mintz G.S., et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92 (2003) 930-935
44. Moscucci M., Fox K., Cannon C., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1815-1823
45. Voeltz M.D., Patel A.D., Feit F., et al. Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary intervention. Am J Cardiol 99 (2007) 1513-1517
46. Dauerman H.L., Lessard D., Yarzebski J., et al. Bleeding complications in patients with anemia and acute myocardial infarction. Am J Cardiol 96 (2005) 1379-1383
47. Skolnick A.H., Alexander K.P., Chen A.Y., et al. Characteristics, management, and outcomes of 5,557 patients age ≥90 years with acute coronary syndromes. J Am Coll Cardiol 49 (2007) 1790-1797
48. Ahmed S., Antman E.M., Murphy S.A., et al. Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials). J Thromb Thrombolysis 21 (2006) 119-129
49. ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin. Lancet 358 (2001) 605-613
50. Wallentin L., Goldstein P., Armstrong P.W., et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting. Circulation 108 (2003) 135-142
51. Antman E.M., Hand M., Armstrong P.W., et al. Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. J Am Coll Cardiol 51 (2008) 210-247
52. Alexander K.P., Chen A.Y., Roe M.T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
53. Devlin G., Gore J.M., Elliott J., et al. Management and 6-month outcomes in elderly and very elderly patients with high-risk non-ST-elevation acute coronary syndromes: GRACE. Eur Heart J 29 (2008) 1275-1282
54. Hochman J.S., Sleeper L.A., Webb J.G., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 341 (1999) 625-634
55. Belkin M., and Bhatt D.L. Carotid stenting in the elderly: is 80 the new 60?. Circulation 119 (2009) 2302-2304
56. Lincoff A.M., Califf R.M., Van de Werf F., et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction. JAMA 288 (2002) 2130-2155
57. O'Shea J.C., Buller C.E., Cantor W.J., et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 287 (2002) 618-621
58. Dauerman H.L., Goldberg R.J., Malinski M., et al. Outcomes and early revascularization for patients ≥65 years of age with cardiogenic shock. Am J Cardiol 87 (2001) 844-848
59. Dauerman H.L., Ryan Jr. T.J., Piper W.D., et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol 15 (2003) 380-384
60. Dzavik V., Sleeper L.A., Cocke T.P., et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 24 (2003) 828-837
61. National Center for Health Statistics. Health, United States, 2008 (2008), Centers for Disease Control and Prevention, Hyattsville (MD)
62. Kemeny M.M., Peterson B.L., Kornblith A.B., et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21 (2003) 2268-2275
63. Tricoci P., Allen J.M., Kramer J.M., et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 301 (2009) 831-841